Sugi Predict

Sugi Predict / Compounds / SCHEMBL641007

SCHEMBL641007

SCHEMBL641007

CC(C)(C)OC(=O)N1CCC(=O)c2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ KDM1A O60341 1/20 0.49
▸ NOTUM Q6P988 2/20 0.49
▸ HDAC1 Q13547 2/20 0.46
▸ HDAC6 Q9UBN7 2/20 0.46
▸ BCHE P06276 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ PDK4 Q16654 1/20 0.44
▸ UCHL1 P09936 1/20 0.41
▸ BUB1 O43683 1/20 0.41
▸ SCN5A Q14524 1/20 0.40
▸ SCN9A Q15858 1/20 0.40
▸ CHRM4 P08173 1/20 0.40
▸ DRD2 P14416 1/20 0.40
▸ HTR7 P34969 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29457581 1.00 LMNA (0.51) LMNARAB9AHTTKDM1ANOTUM
SCHEMBL29960283 0.93 KDM1A (0.48) LMNARAB9AHTTKDM1ANOTUM
SCHEMBL14380662 0.93 KDM1A (0.48) LMNARAB9AHTTKDM1ANOTUM
SCHEMBL16359586 0.87 KDM1A (0.48) LMNARAB9AHTTKDM1ANOTUM
SCHEMBL30667212 0.85 NOTUM (0.64) LMNARAB9AHTTKDM1ANOTUM
SCHEMBL7004709 0.85 NOTUM (0.64) LMNARAB9AHTTKDM1ANOTUM
SCHEMBL2335054 0.84 KDM1A (0.48) RAB9AKDM1ANOTUMHDAC1HDAC6
SCHEMBL22868066 0.82 KDM4E (0.41) LMNAKDM1ANOTUMPDK4BUB1
SCHEMBL19962694 0.82 KDM4E (0.44) LMNAKDM1ANOTUMPDK4BUB1
SCHEMBL31064203 0.81 CHRM4 (0.39) LMNARAB9AHTTKDM1AHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240352021-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2024-10-24 — — US disclosed
EP-3630770-B1 PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS RELAY THERAPEUTICS INC (US) 2024-08-28 — — EP disclosed
EP-3725787-B1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS REGENACY PHARMACEUTICALS INC (US) 2023-11-29 — — EP disclosed
US-20230348389-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS REGENACY PHARMACEUTICALS LLC (US) 2023-11-02 — — US disclosed
US-20230348389-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS REGENACY PHARMACEUTICALS LLC (US) 2023-11-02 — — US disclosed
US-11702389-B2 Piperidine derivatives as HDAC1/2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2023-07-18 — — US disclosed
US-11702389-B2 Piperidine derivatives as HDAC1/2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2023-07-18 — — US disclosed
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-25 — — US disclosed
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-25 — — US disclosed
WO-2023069959-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-04-27 — — WO disclosed
US-5994544-A PRODUCING A 5H-CHROMENO(3,4-F)QUINOLINE LIGAND PHARMACEUTICALS INCORPORATED (US) 1999-11-30 — — US disclosed
US-5696127-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-09 — — US disclosed
US-5696133-A ADMINISTERING COMPOUND WHICH MODULATES ACTIVITY OF PROGESTERONE RECEPTOR LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-09 — — US disclosed
US-5696130-A Tricyclic steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-09 — — US disclosed
US-5693646-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-02 — — US disclosed
US-5693647-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-02 — — US disclosed
US-5688808-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-11-18 — — US disclosed
US-5688810-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-11-18 — — US disclosed
EP-0800519-A1 STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 1997-10-15 — — EP disclosed
WO-1996019458-A2 STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INCORPORATED (US) 1996-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION VIM, ACE, ACE2 LMNA 2116/4885RAB9A 2411/4885HTT 2297/4885
US-11702389-B2 Piperidine derivatives as HDAC1/2 inhibitors HDAC1, HDAC2, HDAC10 LMNA 2773/4885RAB9A 2546/4885HTT 828/4885
US-20230348389-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS HDAC1, HDAC2, HDAC10 LMNA 2773/4885RAB9A 2546/4885HTT 828/4885
US-20240352021-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF EGFR, ERBB2, ERBB3 LMNA 3596/4885RAB9A 2694/4885HTT 3720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.